Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Current and emerging therapies for the treatment of age-related macular degeneration

Authors M Vaughn Emerson, Andreas K Lauer

Published 6 June 2008 Volume 2008:2(2) Pages 377—388

DOI http://dx.doi.org/10.2147/OPTH.S1485

M Vaughn Emerson, Andreas K Lauer

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Abstract: Age-related macular degeneration (AMD) is the leading cause of vision loss in the industrialized world. In the last few decades, the mainstay of treatment for choroidal neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last decade, photodynamic therapy with verteporfin extended treatment for more patients. While both of these treatments have prevented further vision loss in a subset of patients, improvement in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal antibody against VEGF have both shown promising results with improvements in visual acuity with either agent. VEGF trap, a modified soluble VEGF receptor analogue, binds VEGF more tightly than all other anti-VEGF agents and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Other growth factors, including pigment epithelium-derived growth factor that has been administered via an adenoviral vector has shown promising initial results. In some patients ciliary neurotrophic factor is currently being studied for the inhibition of progression of geographic atrophy. Combination therapy has been investigated, and may prove to be more effective in the management of AMD-associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of patients with AMD.

Keywords: age related macular degeneration, macular degeneration, VEGF, VEGF antagonist, anti-VEGF, choroidal neovascularization

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Basic training module for vitreoretinal surgery and the Casey Eye Institute Vitrectomy Indices Tool for Skills Assessment

Yeh S, Chan-Kai BT, Lauer AK

Clinical Ophthalmology 2011, 5:1249-1256

Published Date: 1 September 2011

Electroretinographic findings in transplant chorioretinopathy

Brian T Chan-Kai, Steven Yeh, Richard G Weleber, et al

Clinical Ophthalmology 2010, 4:777-783

Published Date: 14 July 2010

Readers of this article also read:

Effects of exercise timing on sleep architecture and nocturnal blood pressure in prehypertensives

Fairbrother K, Cartner B, Alley JR, Curry CD, Dickinson DL, Morris DM, Collier SR

Vascular Health and Risk Management 2014, 10:691-698

Published Date: 12 December 2014

Pharmacokinetics, tissue distribution, and excretion of zinc oxide nanoparticles

Baek M, Chung HE, Yu J, Lee JA, Kim TH, Oh JM, Lee WJ, Paek SM, Lee JK, Jeong J, Choy JH, Choi SJ

International Journal of Nanomedicine 2012, 7:3081-3097

Published Date: 26 June 2012

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Organic functionalization of single-walled carbon nanotubes (SWCNTs) with some chemotherapeutic agents as a potential method for drug delivery

Ardeshir Khazaei, Mohammad Navid Soltani Rad, Maryam Kiani Borazjani

International Journal of Nanomedicine 2010, 5:639-645

Published Date: 30 August 2010

Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review

Steve Fordan, Philip Raskin

Vascular Health and Risk Management 2009, 5:225-231

Published Date: 19 February 2009

Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization

Clarissa Cola, Salvatore Brugaletta, Victoria Martín Yuste, Bieito Campos, Dominick J Angiolillo, Manel Sabaté

Vascular Health and Risk Management 2009, 5:101-119

Published Date: 11 January 2009

Stress echocardiogaphy: A useful test for assessing cardiac risk in diabetes

Rajan Sharma, Denis Pellerin

Vascular Health and Risk Management 2009, 5:1-7

Published Date: 24 November 2008

Measurement of endothelial function and its clinical utility for cardiovascular risk

Mo Al-Qaisi, Rajesh K Kharbanda, Tarun K Mittal, Ann E Donald

Vascular Health and Risk Management 2008, 4:647-652

Published Date: 6 June 2008